The medical device regulatory system, as well as the medical device market in the European Union (EU), is now facing challenges posed by the newest regulation, Medical device regulations (MDR). Researches have shown concerns and possible consequences related to this new regulation system from both the regulatory approval procedure and market development perspectives. This study aims to elaborate on a practical and objective situation of this latest shift and picture out a predictable scenario for the implementation of future technology like Additive Manufacturing (AM) in healthcare. These two objectives are addressed from the perspective of the core role in this system, Notified Bodies (NBs). Specifically, it answers the following questions: What is the impact of the MDR on the NBs’ operations? What is the impact of the MDR on the device building on AM from NBs’ perspective? A literature review is conducted on existing researches in the relevant fields mentioned in the research questions of this study. Then a self-completion questionnaire is generated and sent to NBs who offer the CE marking granting service for the medical devices around the EU. The eight responses for the survey indicate that the MDR influences NBs and the device building on AM from several perspectives. For the NBs, the number of NBs will decrease while the workload and new recruitment will increase. Also, the independence and competences of NBs will be improved by MDR. In the case of AM-relevant medical devices, MDR will pose specific issues on them while the market will be developed by ensuring the product quality and raising public awareness. These findings are valuable practical evidence to examine the application of MDR and the implementation of technology like AM in healthcare under MDR. Overall, it found that the MDR will cause a tough situation in the short term. At the same time, the far-reaching influence for the regulatory system, as well as the medical device market, is affirmative and expectable worthy.

No description available.

The New Medical Device Regulations (MDR) will become affective on 26 May, 2021. The new regulation entails higher requirements for companies that develop medical devices, but also for all parties involved in the medical device industry. The strengthened requirements mean that it will be more difficult to meet all the criteria for placing medical devices on the market. This thesis has been carried out on behalf of the Swedish Institute for Standards (SIS) and examines companies' transition to MDR and how companies can get support from SIS, but also by other organizations and authorities. A qualitative literature study and document study has been carried out to ponder interview questions, which have then been answered by companies, authorities and organizations who are in one way or another affected by the transition to MDR. Part of the work was also to find out how the companies, depending on size, differ from each other to comply with the new regulation. The results showed that the transition to MDR differs significantly between all the interviewed parties, but that everyone agrees that standardization is important. / Den nya förordningen om medicintekniska produkter (MDR) kommer att träda i kraft den 26 maj, 2021. Den nya förordningen innebär högre krav på företag som utvecklar medicintekniska produkter, men även på alla inblandade parter i den medicintekniska industrin. De stärkta kraven innebär att det kommer vara svårare att uppfylla alla kriterier för att kunna placera medicintekniska produkter på marknaden. Detta examensarbete har utförts på uppdrag av Svenska Institutet för Standarder (SIS) och undersöker företagens övergång till MDR och hur företag kan få stöd, bland annat av SIS, men också av andra organisationer och myndigheter. Det har genomförts en kvalitativ litteraturstudie och dokumentstudie för att formulera intervjufrågor som sedan har besvarats av företag, myndigheter och organisationer som på ett eller annat sätt blir påverkade vid övergången till MDR. En del av arbetet var även att ta reda på hur företagen, beroende på storlek, skiljer sig mellan varandra vad gälleratt uppfylla det nya regelverket. Resultatet visade att övergången till MDR skiljer sig markant mellan alla de intervjuade parterna, men att alla är eniga om att standardisering är viktigt.